Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
August 4, 2020 9:10 AM EDTPiper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining an Overweight rating, citing Ingrezza sales and volumes, a cinrecerfront Phase III study in CAH patients, an increasingly deep pipeline, and the low rates of TD... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat
August 3, 2020 4:42 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.42, $0.69 better than the analyst estimate of $0.73. Revenue for the quarter came in at $302.4 million versus the consensus estimate of $260.52 million.
"I want to thank healthcare providers and our employees for the perseverance they showed... More
